Article Text

Download PDFPDF
Original research
Twelve-year single critical care center experience of nicardipine prolonged-release implants in patients with subarachnoid hemorrhage: a propensity score matching analysis
  1. Yasuhiro Kuroi1,
  2. Hidenori Ohbuchi1,
  3. Naoyuki Arai1,
  4. Yuichi Takahashi1,
  5. Shinji Hagiwara1,
  6. Atsushi Sasahara1,
  7. Ayako Funaki2,
  8. Toshimasa Itoh2,
  9. Yasunori Sato3,
  10. Hidetoshi Kasuya1
  1. 1 Department of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
  2. 2 Department of Pharmacy, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
  3. 3 Department of Preventive Medicine and Public Health, Keio University School of Medicine Graduate School of Medicine, Tokyo, Japan
  1. Correspondence to Professor Hidetoshi Kasuya, Department of Neurosurgery, Tokyo Women's Medical University Medical Center East, Arakawa-ku, Tokyo 116-8567, Japan; hkasuya{at}


Objective To develop a nicardipine prolonged-release implant (NPRI) to prevent cerebral vasospasm in patients with subarachnoid hemorrhage in 1999, which may be used during craniotomy, and report the results of our recent 12-year single critical care center experience.

Methods Of 432 patients with aneurysmal subarachnoid hemorrhage treated between 2007 and 2019, 291 were enrolled. 97 Patients were aged >70 years (33%), 194 were female (67%), 138 were World Federation of Neurological Societies grades 1, 2, and 3 (47%), 218 were Fisher group 3 (75%), and 243 had an anterior circulation aneurysm (84%). Using a propensity score matching method for these five factors, the severity of cerebral vasospasm, occurrence of delayed cerebral infarction, and modified Rankin Scale (mRS) score at discharge were analyzed.

Results One hundred patients each with or without NPRI were selected, and the ratios of coil/clip were 0/100 and 88/12, respectively. Cerebral vasospasm and delayed cerebral infarction were both significantly less common in the NPRI group (p=0.004, OR=0.412 (95% CI 0.223 to 0.760) and p=0.005, OR=0.272 (95% CI 0.103 to 0.714, respectively); a significant difference was seen in the mRS score at discharge by Fisher’s exact test (p=0.0025). A mRS score of 6 (dead) was less common in the group with NPRI, and mRS scores of 0 and 1 were also less common. No side effects were seen.

Conclusions NPRIs significantly reduced the occurrence of cerebral vasospasm and delayed cerebral infraction without any side effects. The NPRI and non-NPRI groups showed different patterns of short-term outcomes in the single critical care center, which might have been due to selection bias and patient characteristics. Differences in outcomes may become clear in comparisons with patients treated by craniotomy.

  • aneurysm
  • complication
  • stroke

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Conception and design: HK. Acquisition of data: AS, HO, NA, YT. Analysis and interpretation of data: HO, NA, YT. Drafting the article: YK, HK. Critically revising the article: YK, SH. Reviewed submitted version of the manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: HK. Statistical analysis: YS. Drug supply: AF, TI. Study supervision: HK.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data sharing not applicable as no datasets generated and/or analyzed for this study. No data are available.